Currently, the FDA approves only one medication specifically for treating hypoactive sexual desire disorder (HSDD) in premenopausal women: Flibanserin (Addyi). It works by affecting brain neurotransmitters, aiming to increase sexual desire. Important: Flibanserin requires a prescription and carries potential side effects, including dizziness and nausea. Your doctor will discuss risks and benefits.
Beyond Flibanserin: Other Approaches
While no other drugs hold FDA approval specifically for female sexual dysfunction, certain medications prescribed for other conditions may sometimes help. For example, some women find relief with low doses of testosterone therapy (for those with low levels) or antidepressants, particularly those affecting serotonin and norepinephrine. However, these are off-label uses, meaning the FDA hasn’t specifically approved them for this purpose. Consult your healthcare provider to assess if they’re appropriate for your situation and to carefully weigh potential benefits against risks.
Treatment Options Summary
| Flibanserin (Addyi) | Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women | Approved | Prescription required; potential side effects exist. |
| Testosterone Therapy (low dose) | Low libido associated with low testosterone levels | Off-label use | Requires careful monitoring of hormone levels. |
| Certain Antidepressants | Sometimes used for improved sexual function | Off-label use | Effectiveness varies; may cause side effects. |
Seeking Professional Guidance
Remember that female sexual dysfunction can have various underlying causes. A thorough evaluation by a healthcare professional is vital for determining the most suitable course of action. They can assess your individual needs and discuss all available treatment options, including therapies focused on relationship dynamics or addressing psychological factors impacting sexual function.
